Journal: Frontiers in Oncology

Article Title: A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies

doi: 10.3389/fonc.2022.889789

Figure Lengend Snippet: Histopathology, tumor growth characterization, and immunostainings (IHC) of representative PDX models from the RCC PDX panel. (A) Histological examination of patient and PDX tissue from the first (P1) and third (P3) PDX in vivo passage. FFPE tissue was used for 5-µm sections and standard H&E stainings. (B) Tumor growth characteristic of untreated control mice reflecting the heterogeneous biology of RCC regardless of the molecular phenotype. Data from twenty-two RCC PDX models utilized for drug testing studies as mean TV ± SEM, n = 3–6. (C) Representative IHC analyses from RCC in vivo passaged PDX tumors for Ki-67 (proliferation), CD31 or PECAM1 (blood vessels), and Pax2 and Pax8 (renal marker). The brown staining indicates the positivity for the respective markers within the tissue. Scale bar = 100 µm. (D) Exemplary RCC PDX growth curves showing individual TV growth characteristic during in vivo passaging (PT = primary tumor passage, P1–P4 indicate consecutive PDX tumor passages). (E) The gene expression-based ccRCC risk model (S3 score) was calculated for primary tumors and metastases from tissue of the Tübingen cohort collected for PDX generation. In 16 of the 24 cases shown, the PDX establishment was successful. The risk categories of the S3 score are represented by the background color. A high S3 score is equivalent to a good prognosis, while a low S3 score corresponds to a poor prognosis in terms of cancer-specific survival, indicating a correlation between S3 score and successful PDX establishment.

Article Snippet: Tissue incubation with primary antibodies— Ki-67 polyclonal rabbit anti-human Ki-67 antigen (Abcam #ab15580, Germany), CD31 polyclonal rabbit anti-human (Abcam #ab28364, Germany), and rabbit anti-human Pax2 and Pax8 (#PI593C002 and #PI924C002, DCS, Germany)—was conducted 45 min at RT.

Techniques: Histopathology, In Vivo, Control, Marker, Staining, Passaging, Expressing